Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 44,745 | 20,746 | 19,967 | 12,880 | 12,455 |
| Cost of Goods | 2,996 | 1,319 | 1,879 | 1,679 | 1,702 |
| Gross Profit | 41,749 | 19,427 | 18,088 | 11,201 | 10,753 |
| Operating Expenses | 153,297 | 129,771 | 140,545 | 128,749 | 138,511 |
| Operating Income | -110,552 | -110,025 | -121,578 | -116,869 | -127,056 |
| Other Income | 9,849 | 10,914 | 12,523 | 13,436 | 15,036 |
| Pre-tax Income | -100,703 | -99,111 | -109,055 | -103,433 | -112,020 |
| Net Income Continuous | -100,703 | -99,111 | -108,039 | -103,433 | -112,020 |
| Net Income | $-100,703 | $-99,111 | $-108,039 | $-103,433 | $-112,020 |
| EPS Basic Total Ops | -1.69 | -1.69 | -1.86 | -1.78 | -1.93 |
| EPS Basic Continuous Ops | -1.69 | -1.69 | -1.85 | -1.78 | -1.93 |
| EPS Diluted Total Ops | -1.69 | -1.69 | -1.86 | -1.78 | -1.93 |
| EPS Diluted Continuous Ops | -1.69 | -1.69 | -1.85 | -1.78 | -1.93 |
| EPS Diluted Before Non-Recurring Items | -1.69 | -1.69 | -1.85 | -1.78 | -1.93 |
| EBITDA(a) | $-110,329 | $-109,806 | $-122,065 | $-117,169 | $-128,217 |